Gelteq Embarks on Preclinical Trial for a Game-Changing Gel
Gelteq Limited, a company based in Melbourne, has exciting news for those who struggle with allergies. This innovative firm specializes in gel-based oral delivery solutions, and today they announced the initiation of a preclinical bioequivalence study. This study will assess a pioneering gel-based formulation of a widely used antihistamine aimed at effectively treating allergy symptoms.
Collaborating with Industry Leaders
The preclinical study is set to take place with Adgyl Lifesciences, a partner of Eurofins Advinus, recognized for their expertise in preclinical contract research services. This collaboration highlights Gelteq's commitment to leveraging industry expertise to ensure the success of their product development.
Pathway to Clinical Trials and FDA Approval
Should the results of the preclinical trials prove successful, Gelteq intends to progress to human clinical trials. They are focusing on securing approval from the U.S. Food and Drug Administration (FDA) through the 505(b)(2) regulatory pathway. This regulatory strategy is often utilized for drugs that have existing clinical data supporting their use, making it a potentially faster route to market.
Transforming Allergy Treatments
“Our gel-based delivery platform is anticipated to change the landscape for traditional pharmaceutical products, particularly in cases where patient adherence and dosage precision are paramount,” shared Nathan Givoni, the CEO of Gelteq. The allergy market represents a significant opportunity for growth, as many patients prefer formats that are easier to take, especially for children and the elderly.
The Allergy Market and its Opportunities
With over 50 million people in the U.S. affected by allergic conditions annually, the global antihistamine market is substantial. Valued at around USD $9 billion in 2023, it is projected to grow at a 6% annual rate, potentially exceeding USD $12 billion by 2028. The demand for antihistamine treatments extends across various demographics, including pediatric, adult, and even veterinary applications, indicating the breadth of the market’s appeal.
Gelteq's Unique Solution
The proprietary formulations developed by Gelteq focus on overcoming the typical drawbacks associated with traditional tablets and syrups. These include challenges with taste, swallowing difficulties in elderly patients, and the need for precise dosing among pets and animals. Mr. Givoni emphasized the potential benefits of their innovative gel technology, which could enhance the experience of taking allergy medications.
Advantages of Gel-Based Delivery
“Our innovative gel technology holds promise in various aspects such as taste masking, ease of administration, and flexible dosing,” Mr. Givoni added. These characteristics are particularly relevant in pediatric and veterinary scenarios where conventional drug forms can be challenging to administer. Gelteq aims to make allergy treatments more accessible and user-friendly.
About Gelteq Limited
With its headquarters in Melbourne, Gelteq (NASDAQ: GELS) is dedicated to innovating and commercializing gel-based solutions not just for allergy treatments, but also for prescription drugs, nutraceuticals, and various other uses. Their advanced formulation technology aims to resolve issues commonly faced by consumers when it comes to medication adherence and administration.
Contact Information
For more information about Gelteq or their current studies, individuals can reach out through their Investor Relations contact:
Matt Kreps, Darrow Associates IR
Phone: +1-214-597-8200
Email: mkreps@darrowir.com
Frequently Asked Questions
What is Gelteq about?
Gelteq is a clinical and science-driven company that specializes in developing gel-based oral delivery solutions for various applications, including allergy treatments.
What are the benefits of gel-based formulations?
Gel-based formulations can offer advantages like improved palatability, ease of administration, and flexible dosing, making medications more user-friendly.
Why is this preclinical trial significant?
This preclinical trial is a crucial step toward bringing a new antihistamine formulation to market, targeting an area where there are unmet patient needs.
What are the projected market trends for antihistamines?
The global antihistamine market is expected to grow significantly, from approximately USD $9 billion in 2023 to more than USD $12 billion by 2028.
How does Gelteq plan to advance its formulation?
Gelteq aims to progress to human clinical trials following successful preclinical results, seeking FDA approval through the 505(b)(2) pathway.
